SEC Form 4 · accession 0001209191-15-070274

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 9, 2015

Accepted (ET)

Sep 11, 2015 · 9:10 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Sep 9, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Sep 9, 2015	S	800	$130.02	D	354,884	D
Common Stock^F2,F4	Sep 9, 2015	S	8,000	$131.29	D	346,884	D
Common Stock^F2,F5	Sep 9, 2015	S	1,100	$132.35	D	345,784	D
Common Stock^F2,F6	Sep 9, 2015	S	500	$133.41	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Sep 9, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	208,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $130.02 (range $129.78 to $130.68).
F4Open market sales reported on this line occurred at a weighted average price of $131.29 (range $130.79 to $131.78).
F5Open market sales reported on this line occurred at a weighted average price of $132.35 (range $132.06 to $132.52).
F6Open market sales reported on this line occurred at a weighted average price of $133.41 (range $133.08 to $133.75).
F7Fully vested.